Compare LPL & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPL | AXSM |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 12.0B |
| IPO Year | 2004 | 2015 |
| Metric | LPL | AXSM |
|---|---|---|
| Price | $5.57 | $232.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 17 |
| Target Price | N/A | ★ $211.12 |
| AVG Volume (30 Days) | ★ 1.7M | 812.7K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.35 | $57.24 |
| Revenue Next Year | $2.94 | $55.88 |
| P/E Ratio | $25.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.07 | $96.09 |
| 52 Week High | $5.67 | $238.56 |
| Indicator | LPL | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 67.41 |
| Support Level | $4.05 | $179.00 |
| Resistance Level | N/A | $235.10 |
| Average True Range (ATR) | 0.20 | 6.77 |
| MACD | 0.07 | -1.14 |
| Stochastic Oscillator | 92.16 | 75.08 |
LG Display Co Ltd manufacture TFT-LCD and OLED technology-based display panels in a broad range of sizes and specifications mainly for use in IT products (comprising notebook computers, desktop monitors and tablet computers), televisions, mobile devices, including smartphones, as well as auto products, and it are one of the world's suppliers of large-sized OLED television panels. It also manufacture display panels for industrial and other applications, including entertainment systems and medical diagnostic equipment.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.